Teva Pharmaceutical Industries Ltd TEVA
- Employees
- 33,950
- Headquarters
- Tel Aviv
- CEO
- Richard D. Francis
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $17.3B through the costs to a net profit of $1.4B · income statement of the 10-K
TEVA among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
14 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 3, 2026 against Feb 5, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 9 checks found nothing to note
-
Receivables growing faster than revenueReceivables +21.2% ($3.1B to $3.7B) vs revenue +4.3% ($16.5B to $17.3B), +16.9 pts apart
-
Critical audit matters changedNew this year: Long-lived assets impairment assessment - Manufacturing facility in Europe (“Asset Group”) (“As described in Notes 1 and 15 to the consolidated financial statements, the Company recorded an impairment charge of $726 million for long-lived assets in connection with the Asset Group, for the year ended December 31, 2025. Long-lived assets are tested for impairment whenever events or changes in”). No longer listed: Goodwill Impairment Assessment - Teva API reporting unit. Same as last year: Sales Reserves and Allowances (“SR&A”) - Chargebacks and Medicaid in the United States
-
Cash from operations $1.6B vs net income $1.4B (FY ending Dec 31, 2025)
8 more checks with nothing to note
-
Inventory +5.7% ($3.0B to $3.2B) vs revenue +4.3% ($16.5B to $17.3B), +1.4 pts apart
-
Same auditor in both 10-Ks: Kesselman & Kesselman
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
14 paragraphs in Risk Factors that were not in the 10-K filed Feb 5, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
We also expect to continue to experience significant challenges to our global generics business. Governments worldwide continue to implement healthcare regulatory reforms aimed at reducing drug costs, including but not limited to, imposing price caps and other limits on generic medicine pricing and reimbursement policies, including as a…
-
Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
Intense competition may adversely affect our ability to successfully develop and commercialize innovative medicines.
-
Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
We have and will continue to implement changes to optimize our business operations and reallocate resources towards growth opportunities. As part of our Pivot to Growth strategy, in May 2025, we announced the Teva Transformation programs which are expected to generate cost savings for the Company, including by examining practices and…
-
Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
Our adoption of artificial intelligence (“AI”) technologies introduces new risks and uncertainties Our adoption of AI technologies introduces new risks and uncertainties. These include potential inaccuracies or biases in AI outputs, cybersecurity vulnerabilities, and evolving global regulatory requirements governing AI use. Misuse or…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $14.9B | $15.8B | $16.5B | $17.3B |
| Net income | −$2.4B | −$559.0M | −$1.6B | $1.4B |
| Operating cash flow | $1.6B | $1.4B | $1.2B | $1.6B |
| Free cash flow | $1.0B | $842.0M | $749.0M | $1.1B |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$17.3B ▲ 4.3% in FY2025$1.4B in FY2025$1.1B ▲ 53.3% in FY2025
Recent filings
12 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 12, 2026Daniell Richard (Officer, EXECUTIVE VP EUROPEAN COMMERCIAL) gave notice of a planned sale of 20,003 shares worth about $856K Form 144, approximate sale date Nov 11, 2026
-
Planned saleNov 12, 2026Sabag Mark (Officer, EXECUTIVE VP INTERNATIONAL MARKETS COMMERCIAL) gave notice of a planned sale of 44,710 shares worth about $2.0M Form 144, approximate sale date Nov 12, 2026
-
Planned saleNov 10, 2026Francis Richard D. (Officer) gave notice of a planned sale of 250,000 shares worth about $10.7M Form 144, approximate sale date Nov 10, 2026, under a 10b5-1 plan adopted Jun 15, 2026
-
Planned saleNov 9, 2026Daniell Richard (Officer, EXECUTIVE VP EUROPEAN COMMERCIAL) gave notice of a planned sale of 25,000 shares worth about $1.1M Form 144, approximate sale date Nov 9, 2026
-
Planned saleNov 5, 2026Sabag Mark (Officer, EXECUTIVE VP INTERNATIONAL MARKETS COMMERCIAL) gave notice of a planned sale of 46,000 shares worth about $1.9M Form 144, approximate sale date Nov 5, 2026
About the company
Teva Pharmaceutical Industries Ltd, Tel Aviv · from the 10-K filed Feb 3, 2026
- Headquarters
- Tel Aviv
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Nov 3, 2026
- Incorporated in
- Israel
Employees, at the top of the page: "As of December 31, 2025, Teva’s global workforce consisted of 33,950 employees" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 3, 2026 (open at SEC), compared with the 10-K filed Feb 5, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEVA/export.csv") into a cell.